LITERATURE REVIEW: STATUS PERKEMBANGAN PEMBUATAN VAKSIN SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) DENGAN PLATFORM INACTIVATED VIRUS

NANI ERNACI, - (2022) LITERATURE REVIEW: STATUS PERKEMBANGAN PEMBUATAN VAKSIN SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) DENGAN PLATFORM INACTIVATED VIRUS. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.

	Text S_PSSF_A181027_Title.pdf Download (1MB)
	Text S_PSSF_A181027_Chapter1.pdf Restricted to Repository staff only Download (315kB)
	Text S_PSSF_A181027_Chapter2.pdf Restricted to Repository staff only Download (419kB)
	Text S_PSSF_A181027_Chapter3.pdf Restricted to Repository staff only Download (433kB)
	Text S_PSSF_A181027_Chapter4.pdf Restricted to Repository staff only Download (575kB)
	Text S_PSSF_A181027_Chapter5.pdf Restricted to Repository staff only Download (182kB)
	Text S_PSSF_A181027_Appendix.pdf Restricted to Repository staff only Download (256kB)

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) adalah virus yang menyerang sistem pernapasan sehingga menyebabkan terjadinya Coronavirus disease 2019 (COVID-19). Inactivated virus adalah salah satu platform yang digunakan untuk pengembangan vaksin SARS-CoV-2. Tujuan penelitian ini untuk memberikan informasi mengenai perkembangan vaksin SARS-CoV-2 yang menggunakan platform Inactivated virus, dan memberikan informasi cara pembuatan (drugs substance dan drugs product) dan efektifitas jenis vaksin ini. Metode penelitian dalam artikel review ini menggunakan penelusuran dengan database PubMed, dan Google Scholar. Hasil penelitian didapatkan informasi perkembangan vaksin SARSCoV-2 dengan platform inactivated virus beberapa vaksin yang sedang dilakukan uji klinis fase 4, vaksin tersebut diantaranya vaksin CoronaVac, Inactivated SARS-CoV-2 vaccine (Vero cell) dan BBIBP-CorV. Bedasarkan hasil uji klinik vaksin dengan platform ini menghasilkan tingkat efikasi >50%. Vaksin CoronaVac efektif melawan virus SARS-CoV-2 varian gamma, Delta dan Omicron dengan efektivitas 46,8%, 59%, dan 38,2%. Drugs substance dibuat dengan memformulasikan strain virus SARS-CoV-2 yang diinaktivasi dengan β-propiolakton atau dengan formaldehid dan diberikan tambahan Aluminium hidroksida, Algel, atau CpG 108 sebagai adjuvant. --- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a virus that attacks the respiratory system, causing Coronavirus disease 2019 (Covid-19). Inactivated virus is one of the platforms used to develop the SARS-CoV-2 vaccine. This research aimed to inform about the SARS-CoV-2 vaccine development using inactivated virus platform and to provide information on how to produce (drugs substance and drugs product) and the effectiveness of this type of vaccine. This article review applied a search using the PubMed database and Google Scholar as the research method. The results of the study obtained information on the development of the SARS-CoV-2 vaccine by an inactivated virus platform for several vaccines currently undergoing phase 4 clinical trials, the vaccines include the CoronaVac vaccine, Inactivated SARS-CoV-2 vaccine (Vero cell) and BBIBP-CorV. Based on the results of clinical trials of vaccines with this platform, the efficacy rate was >50%. The CoronaVac vaccine was effective against the SARS-CoV-2 variants of gamma, Delta and Omicron with 46.8%, 59%, and 38.2% effectiveness. The drug's substance was prepared by formulating the SARS-CoV-2 virus strain which is inactivated with β-propiolactone or formaldehyde and added with Aluminum hydroxide, Algal, or CpG 108 as an adjuvant.

Item Type:	Thesis (Skripsi)
Uncontrolled Keywords:	SARS-CoV-2, Vaksin, Inactivated Platform, Uji Praklinik, Uji Klinik, Efikasi, Efektivitas --- SARS-CoV-2, Vaccine, Inactivated Platform, Praclinical Trial, Clinical Trial, Efficacy, Effectiveness
Subjects:	Q Science > Q Science (General) R Medicine > R Medicine (General)
Divisions:	Program Studi S1 Farmasi
Depositing User:	pustakawan - -
Date Deposited:	14 Sep 2024 13:29
Last Modified:	14 Sep 2024 13:29
URI:	http://repository.stfi.ac.id/id/eprint/1202

Actions (login required)

View Item